Clinical Trials Arena on MSN

Wave’s stock crashes 50% on Phase I obesity data

Despite the Phase I data being less impressive than expected, Wave will still initiate the Phase IIa portion of the study.
NAI500

Wave Life Sciences’ Weight Loss Drug Phase 1 Clinical Data Triggers Stock Volatility, Yet Differentiated Path Still Shows Promise

Shares of small biotech company Wave Life Sciences (WVE) have recently fallen sharply following the release of Phase 1 ...

WAVE Life Sciences Shares Phase 1 WVE-007 Data Showing Visceral Fat Loss, Muscle Preservation Signal

WAVE Life Sciences (NASDAQ:WVE) highlighted positive interim data from the ongoing Phase 1 INLIGHT trial of WVE-007, a GalNAc ...
BioSpace

Wave Stock Cut in Half on Underwhelming Higher Dose Obesity Data

While participants on a lower dose of Wave Life Sciences’ RNA therapy lost 5.3% total fat at the six-month mark, those ...
Knowridge Science Report

Did gravitational waves create dark matter? A new theory looks back to the beginning of time

Scientists have long been puzzled by one of the biggest mysteries in the universe: dark matter. Now, a new study suggests ...
Nasdaq

Wave Life Sciences: Phase 2 FORWARD-53 Achieves All Trial Goals - Quick Facts

(RTTNews) - Wave Life Sciences (WVE) reported positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular ...

Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity Transcript

Hello, and welcome to Wave Life Sciences Positive Interim Phase I Clinical Data from INLIGHT Trial of WVE-007 for Obesity Call. [Operator Instructions] Also, as a reminder, this conference is being ...